Sparfloxacin

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Sparfloxacin

---

CLASS

Quinolone

---

TARGET PROTEIN

DNA gyrase

---

MECHANISM OF ACTION

Bactericidal activity

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Experimental

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/10660507/

https://pubmed.ncbi.nlm.nih.gov/32091697/

---

SIMILAR TARGETS IN OTHER SPECIES

DNA gyrase subunit A and DNA topoisomerase 4 subunit A ~ Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)

---

DRUG BANK ID

DB01208

---

EXTERNAL LINKS

Human Metabolome Database HMDB0015339

KEGG Drug D00590

KEGG Compound C07662

PubChem Compound 60464

PubChem Substance 46506453

ChemSpider 54517

BindingDB 50366822

RxNav 18469

ChEBI 9212

ChEMBL CHEMBL850

ZINC ZINC000000538362

Drugs.com Drugs.com Drug Page  https://www.drugs.com/mtm/sparfloxacin.html

Wikipedia Sparfloxacin

---

REFERENCE

Thangaraj, H. S., Adjeib, O., Allen, B. W., Portaels, F., Evans, M. R. W., Banerjee, D. K., & Wansbrough-Jonesa, M. H. (2000). In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. The Journal of Antimicrobial Chemotherapy, 45(2), 231?233. https://doi.org/10.1093/JAC/45.2.231



Pluschke, G., & R?ltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4

---